Prognosis of Stage IV Sporadic Pancreatic Neuroendocrine Tumors (pNET): Tumor Slope is Prognostic Together with Tumor Burden and Grade

#1452

Introduction: Currently, no prognostic stratification exists in stage IV pNET patients.

Aim(s): To provide prognostic stratification of stage IV pNETs by analyzing 1)prognostic parameters at the time of stage IV diagnosis 2)Per RECIST tumor slope over 3-6 months prior therapy.

Materials and methods: Multicenter retrospective study. Inclusion criteria were: 1)Confirmed pNET naive of therapy 2)Measurable stage IV disease 3)sporadic tumor. Primary endpoint was OS. Two multivariate analyses were performed: model 1 “at the time of stage IV diagnosis”; model 2 "after the characterization of tumor slope".

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Marotta V

Authors: Marotta V, Malka D, Walter T, Do Cao C, Borget I,

Keywords: stage IV, pancreatic neuroendocrine tumor, prognosis, survival,